Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Oct 8 (Reuters) - Bristol-Myers Squibb (BMY.N) on Sunday said it will acquire cancer drug maker Mirati Therapeutics (MRTX.O) for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.
https://www.reuters.com/markets/deals/bristol-myers-squibb-acquire-mirati-48-billion-deal-2023-10-08/#:~:text=Oct%208%20(Reuters)%20%2D%20Bristol,patent%20expirations%20later%20this%20decade.
Johnson & Johnson Vision eyes more innovations, investments in nation
Peter Menziuso, company group chairman for Johnson & Johnson Vision, said during his recent visit to Shanghai: "China is one of our top markets for growth. We will continue to support investments in China."
https://www.chinadaily.com.cn/a/202310/10/WS6524a4a0a31090682a5e7a43.html
Bayer plans to invest more in China
"We can see a lot of innovations in the country … In the pharmaceutical area, new medicines that have been introduced in the United States and Europe can now be also introduced immediately in China,"
https://www.chinadaily.com.cn/a/202310/11/WS6525f2dda31090682a5e7d85.html
I'd like to think that Hutchmed would work to in-license other firms drugs into China to leverage their extensive coverage and sales network. They need to continue to think more flexibly and be dynamic in their path towards becoming profitable as soon as they can. Interesting price movement on NASDAQ today - it was up over 10% a short time ago........
Closed in US bang on where UK closed, China is gradually coming out of post Covid dip - analysts calling markets up from here, US sanctions are largely priced in and fairly limited in scope.
New factory opening should help with margins generally, time to back off on R & D/CAPEX and benefit from past expenditure.
For once the analysts got it right, markets did go up HK around 2% on back of bank stimulus.
Shorts trending down with another drop NASDAQ this time, can be very few if any reasons to go short, reverse and long is the name of the game..
Could end the week starting with a 3..who knows..
HCM certainly has momentum behind it…..but china pharma recent performance has been selective- last 6m
HCM+13%
Innovent +10%
Beigene -23%
Junshi -38%
The continued doldrums for Beigene perhaps presents a rotation opportunity once the gains in HCM and Innovent start to level off. Davey has previously told us Beigene is more expensive on various metrics…although part of that must be the relative maturity of the company and where it is in launching its pipeline.
Looking at your earlier comparisons below Jatw, HCM's relative performance could be due to market consolidation speculation post Takeda deal.
Hedge fund favourite is to go long the strongest player and short the weakest, thereby creating a natural hedge.
------------------------------------------
HCM certainly has momentum behind it…..but china pharma recent performance has been selective- last 6m
HCM+13%
Innovent +10%
Beigene -23%
Junshi -38%
If we take a one year view the figures look slightly different:
HCM+115%
Innovent +71%
Beigene +7.17%
Junshi -22%
Closed at equivalent 306p in HK, pitch up here and make base ready for summit PDUFA ..
Updating with todays six month figures, certainly gaps closing but HCM still out in front by a fair margin.
I can't see how these movements have anything to do with PDUFA decision, this is quite broad rally.
HCM+28%
Innovent +18%
Beigene -0%
Junshi -13%
---------------------------------------------------------
HCM certainly has momentum behind it…..but china pharma recent performance has been selective- last 6m
HCM+13%
Innovent +10%
Beigene -23%
Junshi -38%